Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
Regular Articles

Prognostic Significance of Activated Akt Expression in Pancreatic Ductal Adenocarcinoma

Shinji Yamamoto, Yasuhiko Tomita, Yoshihiko Hoshida, Takaya Morooka, Hiroaki Nagano, Keizo Dono, Koji Umeshita, Masato Sakon, Osamu Ishikawa, Hiroaki Ohigashi, Shoji Nakamori, Morito Monden and Katsuyuki Aozasa
Shinji Yamamoto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yasuhiko Tomita
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoshihiko Hoshida
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takaya Morooka
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroaki Nagano
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keizo Dono
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Koji Umeshita
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masato Sakon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Osamu Ishikawa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroaki Ohigashi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shoji Nakamori
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Morito Monden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katsuyuki Aozasa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1078-0432.CCR-02-1441 Published April 2004
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Purpose: Akt is a serine/threonine kinase that plays a central role in tumorigenesis. Among the members of Akt family, Akt2 is associated with the development of human cancers. The present study was designed to clarify the prognostic significance of Akt2 and activated Akt expression in pancreatic ductal adenocarcinoma (PDAC). In addition, activated extracellular signal-regulated kinase 1 and 2 (ERK1/2) and the proliferation activity of tumor cells detected by Ki-67 immunohistochemistry were examined.

Experimental Design: Immunohistochemical analysis was performed on paraffin-embedded specimens from 65 patients with PDAC; 36 males and 29 females with ages ranging from 48 to 79 years (median, 66 years) of age. Expression levels of Akt2, phosphorylated Akt (p-Akt), and phosphorylated ERK 1/2 (p-ERK 1/2) were categorized as either weaker (low intensity) or equal to stronger (high intensity) compared with those in the endothelial cells of the same specimens. For Ki-67 immunohistochemistry, cases were divided into two groups: level 1, Ki-67 labeling index (LI), <20%; level 2, Ki-67 LI, ≥20%.

Results: Twenty-six (42.6%), 28 (45.9%), 39 (63.9%), and 46 (75.4%) of the tumors showed high intensity of Akt2, p-Akt, and p-ERK 1/2 expression, and Ki-67 LI level 2, respectively. A significant positive correlation was observed between Akt2 and p-Akt expression (P < 0.01). Multivariate analysis revealed that p-Akt expression, Ki-67 LI, and histological differentiation are independent prognosticators for PDAC.

Conclusions: p-Akt expression is a significant prognostic indicator for PDAC. Inhibition of Akt is a possible molecular approach for treatment of PDAC.

INTRODUCTION

Three variations of the serine/threonine kinase Akt are present in the human genome, thus designated as Akt1, Akt2, and Akt3 (1 , 2) . Akt is activated by various growth factors and plays a role in tumorigenesis by inhibiting apoptosis and mediating cell proliferation (1, 2, 3) . Phosphorylation of Thr308 is necessary for Akt activation, and phosphorylation of Ser473 results in maximum activity (4) .

Pancreatic ductal adenocarcinoma (PDAC) usually has a poor prognosis (5, 6, 7) . The altered expression of genes such as the K-ras oncogene frequently occurs during the development of PDAC (8) . However, specific patterns of gene alternations responsible for PDAC have not been identified (9) .

The detection of Akt activation is a useful method for predicting the progression and prognosis of PDAC because it represents the signaling of various growth factors that playing key roles in tumorigenesis (1) . Among the members of the Akt family, Akt2 is associated with the development of human cancers (10) . Overexpression of the Akt2 gene is observed in ∼20% of all cases of PDAC (11) . Transfection of antisense Akt2 RNA into PDAC cell lines inhibits its tumorigenicity (11) . Therefore, an association between the activation or overexpression of Akt, and the clinicopathological behavior of PDAC is postulated.

In the present study, the expression of Akt was immunohistochemically examined in 65 patients with PDAC, and its relationship with clinicopathological factors and the patient survival rate was evaluated. In addition, the activation status of extracellular signal-regulated kinase 1 and 2 (ERK1/2), another serine/threonine kinase that plays a role in cell proliferation and differentiation (12 , 13) , and the proliferation activity of tumor cells seen by using Ki-67 immunohistochemistry (14) was examined.

MATERIALS AND METHODS

Patients.

Sixty-five patients who underwent curative resection of primary PDAC were selected for the study. They underwent surgery at the Gastroenterological Surgery Division, Osaka University Hospital and Division of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases from June 1982 to August 2001. The patients consisted of 36 males and 29 females ranging from 48 to 79 years (median, 66 years) of age. The stage of the disease was classified according to the pathological Tumor-Node-Metastasis staging system (15) .

Surgically resected specimens were macroscopically examined to determine the location and size of the tumors. Then, tissue samples were fixed in 10% formalin and routinely processed for paraffin embedding. Histological sections cut with a 4-μm thickness were stained with H&E and reviewed by one of the authors (Y. Hoshida) to determine histological differentiation and the existence of metastasis in the lymph nodes. All tumors were adenocarcinomas with well- (31 cases), moderately (24 cases), and poorly differentiated (10 cases) morphologies.

After surgery, serum CA 19-9 level was measured, and ultrasonography and computed tomography scan were performed at 3-month intervals. The patients were followed-up until March 31, 2002: the follow-up periods for survivors ranged from 3.4 to 105.5 months (median, 23.6 months) after surgery.

Immunohistochemical Analysis.

The specificity of antiphosphorylated Akt (p-Akt; Thr308) polyclonal antibody (Cell Signaling Technology, Beverly, MA) was examined by Western blot analysis using extracts from Jurkat cells, which showed a positive band after platelet-derived growth factor treatment. Antibody preincubated with antigen peptide was used for a negative control test and gave a uniformly negative result.

The immunoperoxidase procedure (avidin-biotin-complex method) was performed on the paraffin-embedded sections. Antigen retrieval was carried out by heating the sections in 10 mm citrate buffer for 5 min. Anti-Akt2 monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA), anti-p-Akt polyclonal antibody, anti-p-ERK1/2 (Thr202/Tyr204) monoclonal antibody (Cell Signaling Technology), and anti-Ki-67 (clone MIB 1) monoclonal antibody (Dako Cytomation A/S, Copenhagen, Denmark) were used as primary antibodies at dilutions of 1:400, 1:100, 1:100, and 1:50, respectively. Sections were counterstained lightly with methyl green. For negative controls, nonimmunized mouse or rabbit IgG serum (Vector Laboratories, Burlingame, CA) was used as primary antibodies. Positive intracytoplasmic staining of endothelial cells in the noncancerous areas in each specimen was used as an internal positive control. Stained sections were blindly evaluated without prior knowledge of the clinicopathological parameters. The staining intensity in the cytoplasm of the tumor cells was categorized as follows: weaker (low intensity) or equal to stronger (high intensity) than that of the endothelial cells. Cases with negative endothelial cell staining were regarded as having underwent poor antigen preservation and excluded from additional analyses. For Ki-67 immunohistochemistry, cells showing intranuclear staining were judged as Ki-67 positive. The Ki-67-positive cells among 200 tumor cells were counted, and the percentage was used as the Ki-67 labeling index (LI). Cases were divided into two groups: level 1, Ki-67 LI, <20%; level 2, Ki-67 LI, ≥20%.

Statistics.

Statistical analysis was performed using JMP software (SAS Institute, Inc., Cary, NC). χ2 test and Fisher’s exact probability test were used to analyze the correlation between Akt overexpression or activation and clinicopathological features. The Kaplan-Meier method was used to calculate the overall patient survival rate, and the difference in survival curves was evaluated using a log-rank test (16) . Cox’s proportional hazards regression model with stepwise manner was used to analyze the independent prognostic factors (17) . P < 0.05 was considered to be statistically significant.

RESULTS

Akt2, p-Akt, and p-ERK Expression and Ki-67 LI in PDACs.

Four (6.1%) of the 65 cases that did not show endothelial staining for Akt2, p-Akt, or p-ERK were regarded as having undergone poor antigen preservation and were excluded from additional analyses. Twenty-six, 28, and 39 cases showed high intensity staining for Akt2, p-Akt, and p-ERK, respectively, and 46 cases showed Ki-67 LI level 2 (Fig. 1)⇓ .

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

Akt2 (A–C), phosphorylated-Akt (p-Akt; D–F), phosphorylated extracellular signal regulated kinase 1 and 2 (p-ERK 1/2; G–I) immunostaining. A, D, and G, internal controls for Akt2, p-Akt, and p-ERK 1/2 staining. The cytoplasm of endothelial cells is positively stained (magnification, ×50). B, E, and H, low intensity staining of Akt2, p-Akt, and p-ERK 1/2. Tumor cells are weakly stained compared with that of endothelial cells (magnification, ×25). C, F, and I, high intensity staining of Akt2, p-Akt, and p-ERK 1/2. Tumor cells are strongly stained similar to that of endothelial cells (magnification, ×25). J, Ki-67 labeling index (LI) level 1. Less than 20% of the tumor cells show nuclear staining (magnification, ×25). K, Ki-67 LI level 2. More than 20% of the tumor cells show nuclear staining (magnification, ×25).

Univariate and Multivariate Analyses for Prognostic Factors for PDAC.

A significant positive correlation was observed between Akt2 and p-Akt staining patterns (P < 0.01; Table 1⇓ ). Correlation between other combinations was not observed.

View this table:
  • View inline
  • View popup
Table 1

Correlation between Akt2, p-Akta, p-ERK 1/2a, and Ki-67 expression and clinicopathological factors in 61 patients with pancreatic ductal adenocarcinoma

The 5-year overall survival rate for the 61 patients was 32.3%. Patients with low intensity of p-Akt expression showed a significantly better 5-year survival rate (57.0%) than those with high-intensity expression (14.1%; P < 0.05, Fig. 2⇓ ). Akt2 and p-ERK expression were not significant prognosticators. A univariate analysis revealed that p-Akt expression, Ki-67 LI, histological differentiation, and T factor of the pathological Tumor-Node-Metastasis staging system were significant factors of the overall survival rate (Table 2)⇓ . A subsequent multivariate analysis revealed that p-Akt expression, Ki-67 LI, and histological differentiation were independent prognosticators (Table 3)⇓ .

Fig. 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 2.

Overall survival rate of pancreatic ductal adenocarcinoma patients with high and low intensity Akt2 and p-Akt expression. A significant difference was observed between the two groups for p-Akt expression (B; P < 0.05) but not for Akt2 expression [A; nonsignificant (N.S.)].

View this table:
  • View inline
  • View popup
Table 2

Univariate analysis of clinicopathological factors for the overall survival rate of 61 patients with pancreatic ductal adenocarcinoma

View this table:
  • View inline
  • View popup
Table 3

Multivariate analysis of clinicopathological factors for overall survival rate of 61 patients with pancreatic ductal adenocarcinoma

DISCUSSION

To establish proper therapeutic modalities for PDAC, an accurate assessment of the factors affecting tumor progression and patient prognosis is critical. Although the conventional Tumor-Node-Metastasis staging system, which is defined by tumor size, tumor progression, lymph node involvement, and distant metastasis (15) , is useful for PDAC classification, the outcome is poor for patients even in the low-stage (I and II) groups (5) . Therefore, the prognostic use of several molecular markers for PDAC classification have been investigated (8) , although none proved useful for predicting patient prognosis (9) . We undertook the present study to determine whether Akt2, p-Akt, and p-ERK expression and the proliferation activity seen by Ki-67 LI are valid biological indicators of the aggressiveness of PDAC.

The constitutive activation of Akt in endothelial cells is essential for the maintenance of endothelial cell-extracellular matrix attachment (18) . In the present study, Akt2 and p-Akt expressions in endothelial cells were used as an internal positive control for each specimen, which showed a consistent moderate staining intensity. However, the staining intensity of nontumorous pancreatic tissues varied among the samples (data not shown). This is because of the different conditions of pancreatic tissue frequently affected by varying degrees of inflammation and fibrosis.

The patients characteristics such as gender, age, and 5-year survival rates were similar to those in the previous studies from Japan (5 , 6) and Western countries (7) . The present uni- and multivariate analyses confirmed the prognostic significance of tumor differentiation and T-factor for the pathological Tumor-Node-Metastasis classification of PDAC, as previously reported (5 , 7) . Therefore, the results of the present cases are generally applicable to PDAC.

The present study showed a significant correlation between Akt2 and p-Akt for PDAC (P < 0.01), which implies a close association between increased Akt activity and overexpression. Additional investigation is necessary to clarify the mechanism that controls Akt expression and activation.

Uni- and multivariate analyses showed that activated Akt expression is an independent prognosticator for PDAC patients together with histological differentiation and Ki-67 LI. The cause for poor prognosis of PDAC is local recurrence (5, 6, 7) . Pleiotropic Akt activities such as antiapoptosis (3) , proliferation (3) , invasiveness (19) , and angiogenesis (20) provide PDAC a microinvasiveness at the resected margin and promotes the recurrence of cancer. These findings show that activated Akt expression is a sign of poor prognosis for PDAC.

The phosphatase and tensin homologue deleted from chromosome 10 (PTEN) is a tumor suppressor gene that negatively regulates the Akt pathway, and its mutations are often associatedwith an aggressive tumor phenotype (21) . Somatic deletions or mutations of this gene have been identified in a large proportion of tumors, including glioblastomas, and endometrial and prostate cancers, thus placing PTEN among the most commonly mutated genes in human cancers (21) . The decreased expression of PTEN for PDAC occurs at the mRNA and protein levels, whereas deletions or mutations are not frequently observed (22) .

Constitutive activation of the Akt pathway occurs in many human PDAC cell lines (23) . Inhibition of the phosphatidylinositol 3′-kinase/Akt pathway by inhibitors of phosphatidylinositol 3′-kinase (LY294002) induces apoptosis in tumor cells in vitro and inhibits the growth of tumor xenografts in vivo without excessive toxicity in nude mice (23) . In vitro studies showed that Akt activation inhibits gemcitabine-induced apoptosis, and the addition of Akt inhibitors diversely enhances apoptosis (24) . The Akt activation pathway could be a target for the treatment of PDAC.

In conclusion, activated Akt expression determined by immunohistochemistry is a new prognosticator for PDAC and is a new way to explore effective modalities for the treatment of PDAC. The inhibition of Akt might be a possible molecular target for the treatment of PDAC.

Footnotes

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • Requests for reprints: Yasuhiko Tomita, Department of Pathology (C3), Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita Osaka 565-0871, Japan. Phone: 81-6-6879-3711; Fax: 81-6-6879-3719; E-mail: yt{at}molpath.med.osaka-u.ac.jp

  • Received November 23, 2002.
  • Revision received November 17, 2003.
  • Accepted December 10, 2003.

References

  1. ↵
    Murthy SS, Tosolini A, Taguchi T, Testa JR. Mapping of AKT3, encoding a member of the Akt/protein kinase B family, to human and rodent chromosomes by fluorescence in situ hybridization. Cytogenet Cell Genet, 88: 38-40, 2000.
    OpenUrlCrossRefPubMed
  2. ↵
    Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA, 98: 10983-5, 2001.
    OpenUrlFREE Full Text
  3. ↵
    Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev, 13: 2905-27, 1999.
    OpenUrlFREE Full Text
  4. ↵
    Bellacosa A, Chan TO, Ahmed NN, et al Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene, 17: 313-25, 1998.
    OpenUrlCrossRefPubMed
  5. ↵
    Mukaiya M, Hirata K, Satoh T, et al Lack of survival benefit of extended lymph node dissection for ductal adenocarcinoma of the head of the pancreas: retrospective multi-institutional analysis in Japan. World J Surg, 22: 248-52, 1998.
    OpenUrlCrossRefPubMed
  6. ↵
    Takahashi T, Niino N, Ishikura H, Okushiba S, Dohke M, Katoh H. Predictive factors for long-term survival in patients with pancreatic carcinoma. Hepatogastroenterology, 44: 1463-8, 1997.
    OpenUrlPubMed
  7. ↵
    Magistrelli P, Antinori A, Crucitti A, et al Prognostic factors after surgical resection for pancreatic carcinoma. J Surg Oncol, 74: 36-40, 2000.
    OpenUrlCrossRefPubMed
  8. ↵
    Ghaneh P, Kawesha A, Evans JD, Neoptolemos JP. Molecular prognostic markers in pancreatic cancer. J Hepatobiliary Pancreat Surg, 9: 1-11, 2002.
    OpenUrlCrossRefPubMed
  9. ↵
    Hilgers W, Kern SE. Molecular genetic basis of pancreatic adenocarcinoma. Genes Chromosomes Cancer, 26: 1-12, 1999.
    OpenUrlCrossRefPubMed
  10. ↵
    Yuan ZQ, Sun M, Feldman RI, et al Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene, 19: 2324-30, 2000.
    OpenUrlCrossRefPubMed
  11. ↵
    Cheng JQ, Ruggeri B, Klein WM, et al Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci USA, 93: 3636-41, 1996.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell, 80: 179-85, 1995.
    OpenUrlCrossRefPubMed
  13. ↵
    Hunter T. Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling. Cell, 80: 225-36, 1995.
    OpenUrlCrossRefPubMed
  14. ↵
    Ueda T, Aozasa K, Tsujimoto M, et al Prognostic significance of Ki-67 reactivity in soft tissue sarcomas. Cancer (Phila.), 63: 1607-11, 1989.
  15. ↵
    Sobin LH, Wittekind CH. . TNM classification of malignant tumours, 6 ed. 93-6, John Wiley & Sons New York 2002.
  16. ↵
    Kaplan EL, Meier P. Non-parametric estimation for incomplete observations. J Am Stat Assoc, 53: 457-81, 1958.
    OpenUrlCrossRef
  17. ↵
    Cox DR. Regression models and life tables. J R Stat Soc, 34: 187-220, 1972.
    OpenUrl
  18. ↵
    Shiojima I, Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res, 90: 1243-50, 2002.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Park BK, Zeng X, Glazer RI. Akt1 induces extracellular matrix invasion and matrix metalloproteinase-2 activity in mouse mammary epithelial cells. Cancer Res, 61: 7647-53, 2001.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Wu KK. Regulation of endothelial nitric oxide synthase activity and gene expression. Ann NY Acad Sci, 962: 122-30, 2002.
    OpenUrlCrossRefPubMed
  21. ↵
    Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell, 100: 387-90, 2000.
    OpenUrlCrossRefPubMed
  22. ↵
    Ebert MP, Fei G, Schandl L, et al Reduced PTEN expression in the pancreas overexpressing transforming growth factor β1. Br. J Cancer, 86: 257-62, 2002.
    OpenUrlCrossRefPubMed
  23. ↵
    Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, McConkey DJ. Inhibition of the phosphatidylinositol 3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther, 1: 989-97, 2002.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Ng S, Tsao MS, Chow S, Hedley DW. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res, 60: 5451-5, 2000.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Clinical Cancer Research: 10 (8)
April 2004
Volume 10, Issue 8
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Prognostic Significance of Activated Akt Expression in Pancreatic Ductal Adenocarcinoma
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
Citation Tools
Prognostic Significance of Activated Akt Expression in Pancreatic Ductal Adenocarcinoma
Shinji Yamamoto, Yasuhiko Tomita, Yoshihiko Hoshida, Takaya Morooka, Hiroaki Nagano, Keizo Dono, Koji Umeshita, Masato Sakon, Osamu Ishikawa, Hiroaki Ohigashi, Shoji Nakamori, Morito Monden and Katsuyuki Aozasa
Clin Cancer Res April 15 2004 (10) (8) 2846-2850; DOI: 10.1158/1078-0432.CCR-02-1441

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Prognostic Significance of Activated Akt Expression in Pancreatic Ductal Adenocarcinoma
Shinji Yamamoto, Yasuhiko Tomita, Yoshihiko Hoshida, Takaya Morooka, Hiroaki Nagano, Keizo Dono, Koji Umeshita, Masato Sakon, Osamu Ishikawa, Hiroaki Ohigashi, Shoji Nakamori, Morito Monden and Katsuyuki Aozasa
Clin Cancer Res April 15 2004 (10) (8) 2846-2850; DOI: 10.1158/1078-0432.CCR-02-1441
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • INTRODUCTION
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Regular Articles

  • 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitor, Fluvastatin, as a Novel Agent for Prophylaxis of Renal Cancer Metastasis
  • Expression and Functional Role of CCR9 in Prostate Cancer Cell Migration and Invasion
  • Prognostic Impact of Hypoxia-Inducible Factors 1α and 2α in Colorectal Cancer Patients
Show more Regular Articles

Molecular Oncology, Markers, Clinical Correlates

  • Prognostic Impact of Hypoxia-Inducible Factors 1α and 2α in Colorectal Cancer Patients
  • Nuclear Factor-κB Nuclear Localization Is Predictive of Biochemical Recurrence in Patients with Positive Margin Prostate Cancer
  • Transcription Factor AP-2γ Is a Developmentally Regulated Marker of Testicular Carcinoma In situ and Germ Cell Tumors
Show more Molecular Oncology, Markers, Clinical Correlates
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2019 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement